Exploring Possible Drug-Resistant Variants of SARS-CoV‑2 Main Protease (Mpro) with Noncovalent Preclinical Candidate, Mpro61

Exploring Possible Drug-Resistant Variants of SARS-CoV‑2 Main Protease (Mpro) with Noncovalent Preclinical Candidate, Mpro61

Saved in:

Bibliographic Details
Main Authors:	Jessica R. Kenneson, Christina Papini, Su Tang, Kathy Huynh, Chun-Hui Zhang, William L. Jorgensen, Karen S. Anderson
Format:	Article
Language:	English
Published:	American Chemical Society 2025-01-01
Series:	ACS Bio & Med Chem Au
Online Access:	https://doi.org/10.1021/acsbiomedchemau.4c00109
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Molecular Dynamics Simulation of Ligands from Anredera cordifolia (Binahong) to the Main Protease (Mpro) of SARS-CoV-2
by: Jaka Fajar Fatriansyah, et al.
Published: (2022-01-01)

Inhibitory efficacy and structural insights of Bofutrelvir against SARS-CoV-2 Mpro mutants and MERS-CoV Mpro
by: Weiwei Wang, et al.
Published: (2025-03-01)

Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?
by: Matteo Pavan, et al.
Published: (2022-12-01)

The main protease (Mpro) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII
by: Anna Pagotto, et al.
Published: (2025-08-01)

The Thiadiazole Ring (THD) Is a Building Block for Potential Inhibitors of the SARS-CoV-2 Main Protease (Mpro): Theoretical Look into the Structure, Reactivity, and Binding Profile of Three 1,3,4-THD Derivatives toward Mpro
by: Dileep Chikkur Shanthakumar, et al.
Published: (2023-12-01)

Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study
by: Trina Ekawati Tallei, et al.
Published: (2020-01-01)

K36-based inhibitor analogs as potential therapeutics against SARS-CoV-2 main protease (Mpro): a computational investigation
by: Mohamed L. AbouYoussef, et al.
Published: (2025-06-01)

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.
by: Francesco Costacurta, et al.
Published: (2024-09-01)

Synthesis and evaluation of carmofur analogs as antiproliferative agents, inhibitors to the main protease (Mpro) of SARS-CoV-2, and membrane rupture-inducing agents
by: Tiffany Gu, et al.
Published: (2025-04-01)

An Investigation of Nirmatrelvir (Paxlovid) Resistance in SARS-CoV‑2 Mpro
by: Rasha M. Yaghi, et al.
Published: (2024-10-01)

Structural basis for varying drug resistance of SARS-CoV-2 Mpro E166 variants
by: Morgan A. Esler, et al.
Published: (2025-07-01)

Sintesis, Karakterisasi Struktur, dan Kajian In Silico Potensi 2'-Hidroksicalkon dan Flavonol Tersubstitusi Trimetoksi sebagai Inhibitor Main Protease (MPro) SARS-CoV-2
by: Ihsan Ikhtiarudin, et al.
Published: (2024-02-01)

Molecular Recognition of SARS-CoV-2 Mpro Inhibitors: Insights from Cheminformatics and Quantum Chemistry
by: Adedapo Olosunde, et al.
Published: (2025-05-01)

Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 MPro protein - an in silico and cell-based approach
by: Khushboo Singh, et al.
Published: (2025-07-01)

<i>In Silico</i> Development of SARS-CoV-2 Non-Covalent Mpro Inhibitors: A Review
by: Islam Alagawani, et al.
Published: (2025-06-01)

Computational and in vitro evaluation of sumac-derived ©Rutan compounds towards Sars-CoV-2 Mpro inhibition
by: Muzaffar Kayumov, et al.
Published: (2025-02-01)

A novel, covalent broad-spectrum inhibitor targeting human coronavirus Mpro
by: Jing Sun, et al.
Published: (2025-05-01)

IDENTIFICATION OF POTENTIAL ANTIVIRUS FROM Moringa oleifera LEAF AS MPRO SARS-COV-2 INHIBITOR: STUDY OF MOLECULAR DOCKING
by: Zaimi Afandi, et al.
Published: (2022-07-01)

Development of a highly sensitive luciferase assay for intracellular evaluation of coronavirus Mpro activity
by: Bao Dong, et al.
Published: (2025-04-01)

Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning
by: Anacleto Silva de Souza, et al.
Published: (2025-06-01)

Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding
by: Krishna M. Padmanabha Das, et al.
Published: (2025-07-01)

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo
by: Huiping Shuai, et al.
Published: (2025-07-01)

Identification of broad-spectrum Mpro inhibitors: a focus on high-risk coronaviruses and conserved interactions
by: Man Liu, et al.
Published: (2025-12-01)

Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus
by: Baolong Pan, et al.
Published: (2025-04-01)

Marine-Derived Peptides from <i>Phaeodactylum tricornutum</i> as Potential SARS-CoV-2 Mpro Inhibitors: An <i>In Silico</i> Approach
by: David Mauricio Cañedo-Figueroa, et al.
Published: (2025-05-01)

Identifying Natural Products as Feline Coronavirus Mpro Inhibitors by Structural-Based Virtual Screening and Enzyme-Based Assays
by: Zunyun Jiang, et al.
Published: (2025-01-01)

Identification of potential COVID-19 Mpro inhibitors through covalent drug docking, molecular dynamics simulation, and MMGBSA calculation
by: Mohammad Hossein Haghir Ebrahim Abadi, et al.
Published: (2025-07-01)

Highly efficient discovery of the covalent Mpro inhibitors from crude Pu-erh tea by integrating biochemical and chemoproteomic approaches
by: Guanghao Zhu, et al.
Published: (2025-05-01)

Inhibitory Effects of Mangifera indica Secondary Metabolites and Their Synthetic Derivatives against SARS-CoV‑2 Mpro and NS2B/NS3 (ZIKV and DENV-2)
by: Gabriella B. Souza, et al.
Published: (2024-10-01)

Corrigendum to “Favipiravir vs. Deferiprone: tautomeric, photophysical, in vitro biological studies, and binding interactions with SARS-Cov-2-MPro/ACE2” [Curr. Res. Biotechnol. 7 (2024) 100176]
by: Nikolay T. Tzvetkov, et al.
Published: (2025-01-01)

Copper(II) Inhibition of the SARS‐CoV‐2 Main Protease
by: Roberto A. Garza‐López, et al.
Published: (2025-07-01)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
by: Yi Kuang, et al.
Published: (2023-04-01)

Characterization of an unusual SARS-CoV-2 main protease natural variant exhibiting resistance to nirmatrelvir and ensitrelvir
by: Dipendra Bhandari, et al.
Published: (2025-07-01)

Computational Insights into Acrylamide Fragment Inhibition of SARS-CoV-2 Main Protease
by: Ping Chen, et al.
Published: (2024-11-01)

Noncovalent n → π* Interactions in Collagen: The Key for Everlasting Bonds?
by: Marina Rubini
Published: (2024-10-01)

Oxygen reduction reaction on covalently and noncovalently modified carbon nanowalls
by: Roman A. Manzhos, et al.
Published: (2018-12-01)

The SARS-CoV-2 main protease causes mitochondrial dysfunction in a yeast model
by: Wojciech Grabiński, et al.
Published: (2025-07-01)

Is Copper-61 the New Gallium-68? Automation and Preclinical Proof-of-Concept of <sup>61</sup>Cu-Based Radiopharmaceuticals for Prostate Cancer Imaging
by: Diana Rodrigues, et al.
Published: (2025-03-01)

Control of urea release through noncovalent derivatization with aliphatic dicarboxylic acids
by: Tessa Faulks, et al.
Published: (2025-12-01)

Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds
by: Noor Atatreh, et al.
Published: (2025-12-01)